Single-cell characterization of anti–LAG-3 and anti–PD-1 combination treatment in patients with mela...
Single-cell characterization of anti–LAG-3 and anti–PD-1 combination treatment in patients with melanoma
About this item
Full title
Author / Creator
Huuhtanen, Jani , Kasanen, Henna , Peltola, Katriina , Lönnberg, Tapio , Glumoff, Virpi , Brück, Oscar , Dufva, Olli , Peltonen, Karita , Vikkula, Johanna , Jokinen, Emmi , Ilander, Mette , Lee, Moon Hee , Mäkelä, Siru , Nyakas, Marta , Li, Bin , Hernberg, Micaela , Bono, Petri , Lähdesmäki, Harri , Kreutzman, Anna and Mustjoki, Satu
Publisher
United States: American Society for Clinical Investigation
Journal title
Language
English
Formats
Publication information
Publisher
United States: American Society for Clinical Investigation
Subjects
More information
Scope and Contents
Contents
BackgroundRelatlimab plus nivolumab (anti-lymphocyte-activation gene 3 plus anti-programmed death 1 [anti-LAG-3+anti-PD-1]) has been approved by the FDA as a first-line therapy for stage III/IV melanoma, but its detailed effect on the immune system is unknown.MethodsWe evaluated blood samples from 40 immunotherapy-naive or prior immunotherapy-refra...
Alternative Titles
Full title
Single-cell characterization of anti–LAG-3 and anti–PD-1 combination treatment in patients with melanoma
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_45e8a21ae8814471ba60e41684de20f1
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_45e8a21ae8814471ba60e41684de20f1
Other Identifiers
ISSN
1558-8238,0021-9738
E-ISSN
1558-8238
DOI
10.1172/JCI164809
